文献速递肝病

磁共振成像质子密度脂肪分数测量与病理学家分配的成人非酒精性脂肪性肝炎肝活检脂肪变性分级之间的一致性

Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
PubMed 文献 · Gastroenterology · 2017-06-15

本研究基于113名成人非酒精性脂肪性肝炎(NASH)患者的多中心2b期随机双盲安慰剂对照试验数据,评估MRI质子密度脂肪分数(PDFF)在分级肝脂肪变性和评估其变化方面的诊断性能,以中心病理学为参考。结果显示PDFF能准确分类肝脂肪变性分级及其变化。

要点

  • 基线时PDFF均值随组织学脂肪变性分级增加而升高:0-1级9.8%±3.7%,2级18.1%±4.3%,3级30.1%±8.1%。
  • PDFF区分脂肪变性0-1级与2-3级的AUROC为0.95(95%CI 0.91-0.98),区分0-2级与3级的AUROC为0.96(95%CI 0.93-0.99)。
  • 72周后PDFF变化识别脂肪变性分级降低的AUROC为0.81(95%CI 0.71-0.91),识别分级升高的AUROC为0.81(95%CI 0.63-0.99)。

核心结论

  • 基于成人NASH的2期随机对照试验数据,不同场强和不同中心的MRI扫描仪测得的PDFF,在以活检组织学分析为参考时,能准确分类肝脂肪变性分级及其变化。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照的2b期试验,纳入113名成人NASH患者,比较奥贝胆酸与安慰剂的疗效。
  • 在基线和72周后通过肝活检和MRI(不同制造商的1.5T或3T扫描仪)评估肝脂肪变性。
  • 组织学脂肪变性分级由病理委员会共识评分,采用交叉验证的受试者工作特征(ROC)分析。

主要发现

  • 基线时34%的受试者为脂肪变性0或1级,39%为2级,27%为3级;对应的平均PDFF值分别为9.8%±3.7%、18.1%±4.3%和30.1%±8.1%。
  • PDFF分类脂肪变性0-1级 vs 2-3级的AUROC为0.95(95%CI 0.91-0.98),分类0-2级 vs 3级的AUROC为0.96(95%CI 0.93-0.99)。
  • 在90%特异性下,PDFF区分2-3级的截断值为16.3%,区分3级的截断值为21.7%,相应敏感性分别为83%和84%。
  • 72周奥贝胆酸 vs 安慰剂后,42%的受试者脂肪变性分级降低(PDFF较基线平均降低7.4%±8.7%),49%分级无变化(PDFF较基线平均增加0.3%±6.3%),9%分级升高(PDFF较基线平均增加7.7%±6.0%)。
  • PDFF变化识别脂肪变性分级降低的AUROC为0.81(95%CI 0.71-0.91),识别分级升高的AUROC为0.81(95%CI 0.63-0.99);PDFF降低5.15%识别分级降低的敏感性为58%、特异性为90%,PDFF升高5.6%识别分级升高的敏感性为57%、特异性为90%。

关键数值与推荐

  • PDFF区分脂肪变性0-1级 vs 2-3级的AUROC为0.95(95%CI 0.91-0.98)。
  • PDFF区分脂肪变性0-2级 vs 3级的AUROC为0.96(95%CI 0.93-0.99)。
  • 在90%特异性下,PDFF区分2-3级的截断值为16.3%,敏感性83%;区分3级的截断值为21.7%,敏感性84%。
  • PDFF降低5.15%识别脂肪变性分级降低的敏感性58%、特异性90%;PDFF升高5.6%识别分级升高的敏感性57%、特异性90%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We assessed the diagnostic performance of magnetic resonance imaging (MRI) proton density fat fraction (PDFF) in grading hepatic steatosis and change in hepatic steatosis in adults with nonalcoholic steatohepatitis (NASH) in a multi-center study, using central histology as reference. METHODS: We collected data from 113 adults with NASH participating in a multi-center, randomized, double-masked, placebo-controlled, phase 2b trial to compare the efficacy cross-sectionally and longitudinally of obeticholic acid vs placebo. Hepatic steatosis was assessed at baseline and after 72 weeks of obeticholic acid or placebo by liver biopsy and MRI (scanners from different manufacturers, at 1.5T or 3T). We compared steatosis estimates by PDFF vs histology. Histologic steatosis grade was scored in consensus by a pathology committee. Cross-validated receiver operating characteristic (ROC) analyses were performed. RESULTS: At baseline, 34% of subjects had steatosis grade 0 or 1, 39% had steatosis grade 2, and 27% had steatosis grade 3; corresponding mean PDFF values were 9.8%±3.7%, 18.1%±4.3%, and 30.1%±8.1%. PDFF classified steatosis grade 0-1 vs 2-3 with an area under the ROC curve (AUROC) of 0.95 (95% CI, 0.91-0.98), and grade 0-2 vs grade 3 steatosis with an AUROC of 0.96 (95% CI, 0.93-0.99). PDFF cut-off values at 90% specificity were 16.3% for grades 2-3 and 21.7% for grade 3, with corresponding sensitivities of 83% and 84%. After 72 weeks' of obeticholic vs placebo, 42% of subjects had a reduced steatosis grade (mean reduction in PDFF from baseline of 7.4%±8.7%), 49% had no change in steatosis grade (mean increase in PDFF from baseline of 0.3%±6.3%), and 9% had an increased steatosis grade (mean increase in PDFF from baseline of 7.7%±6.0%). PDFF change identified subjects with reduced steatosis grade with an AUROC of 0.81 (95% CI, 0.71-0.91) and increased steatosis grade with an AUROC of 0.81 (95% CI, 0.63-0.99). A PDFF reduction of 5.15% identified subjects with reduced steatosis grade with 90% specificity and 58% sensitivity, whereas a PDFF increase of 5.6% identified those with increased steatosis grade with 90% specificity and 57% sensitivity. CONCLUSIONS: Based on data from a phase 2 randomized controlled trial of adults with NASH, PDFF estimated by MRI scanners of different field strength and at different sites, accurately classifies grades and changes in hepatic steatosis when histologic analysis of biopsies is used as a reference.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Middleton MS, Heba ER, Hooker CA, et al. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. Gastroenterology. 2017. PMID: 28624576. doi:10.1053/j.gastro.2017.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。